Aerie Pharmaceuticals — Investor Presentation (January 2022)
33 slides from Aerie Pharmaceuticals's investor presentation, Jan 5, 2022

Slide 1: An Emerging Leader in Ophthalmology
Exhibit 99.1 AERIE An Em e r g i n g L e a d e r i n O p h t h a l m o l o g y Ja n u a ry 2 0 2 2 For Investor Use Only 1

Slide 2: Disclaimer
Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie in this presentation are qualified in their ent

Slide 3: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology ® ® Rhopressa /Rocklatan Growing Glaucoma franchise: Commercial-Stage • U.S.: Net Sales >$115MM+ U.S. run-rate as of Q3:2021 Ophthalmology Company • ROW: Partnership with Santen: EU: Approved, Japan: Phase 3 Two Phase 3-ready programs (in Dry Eye and in DME) Diffe

Slide 4: Novel Mechanisms for Products/Pipeline
Novel Mechanisms for Products/Pipeline Glaucoma: ROCK inhibition To provide a unique improvement 1 Wet AMD : Pan-VEGF-R inhibitor in fluid outflow Angiogenesis inhibitor Dry Eye: TRPM8 agonist To increase tear production 2 DME : Bioerodible dexamethasome retinal implant To reduce inflammation and ma

Slide 5: Aerie Product Pipeline Targets Attractive Commercial Markets
Aerie Product Pipeline Targets Attractive Commercial Markets ® Two Phase 3 Ready Programs plus “PRINT ” Technology Platform Product/Indication R&D Phase 1 Phase 2 Phase 3 Regulatory Status/Next Steps ® Rhopressa / On the Market in U.S. ® Rocklatan : Approved in EU, Phase 3 in Japan Glaucoma AR-15512

Slide 6: Glaucoma: ~$3B U.S. Market
1 Glaucoma: ~$3B U.S. Market Reduced THE PROBLEM fluid • Stiffening trabecular meshwork reduces normal drainage outflow • Increased intraocular Pressure (IOP) can damage the optic nerve Increased and lead to vision loss intra-ocular pressure THE OPPORTUNITY • 34MM prescriptions annually, 55MM bottle

Slide 7: Rhopressa Delivers an Additional 20% IOP Reduction
® Rhopressa Delivers an Additional 20% IOP Reduction Just ONE DROP a day 1 Real-world Multi-center Open Label Study (M.O.S.T.) Mean IOP (mmHg) over 12 weeks : Reduction in IOP: • 20% (More than 4 mmHg) • Regardless of current 1 regimen or baseline pressure A reduction of 1 mmHg in IOP has been shown

Slide 8: Rocklatan Potential to be Best-in-Class for Glaucoma Care
® Rocklatan Potential to be Best-in-Class for Glaucoma Care ® Rocklatan (netarsudil/latanoprost combo) is the only 1 once-daily, fixed-dose combination treatment in the U.S. 1,2 Achieves superior IOP reduction vs. latanoprost-- the 2 world’s most prescribed glaucoma treatment Effective, regardless o

Slide 9: Rhopressa/Rocklatan U.S. Revenue at a >$115MM Run Rate
® ® Rhopressa /Rocklatan U.S. Revenue at a >$115MM Run Rate Actual weekly sales-out to Pharmacies IQVIA Weekly Data as of 12/24/2021 Data as of 12/24/2021 Growth Drivers: 30,000 30,000 24,963 Increasing reimbursement 25,000 25,000 21,188 Increasing prescriber 20,000 20,000 adoption/refill Rx Growing

Slide 10: U.S. Commercial Strategy Focused on Driving Earlier Adoption
U.S. Commercial Strategy Focused on Driving Earlier Adoption in Appropriate Patients Eye Care Practitioner Patient Payor Support includes co-pay card Focus on top prescribers, Commercial Coverage at 76% ® for commercially insured representing >75% of the and growing for Rhopressa and ® patients glau

Slide 11: Dry Eye: ~$1.6B U.S. Market
1 Dry Eye: ~$1.6B U.S. Market Inadequate tear THE PROBLEM production & quality • The need for a chronic treatment that can provide rapid and more effective relief of Dry Eye symptoms TRPM8 receptor THE OPPORTUNITY • 30MM patients (18MM diagnosed) • <10% treated by Rx TRPM8 agonism leads to: Stimulat

Slide 12: AR-15512 Phase 2b Trial Design
AR-15512 Phase 2b Trial Design Objective: To evaluate the safety, tolerability, and efficacy of AR-15512 compared to vehicle administered twice daily in subjects with dry eye disease. Design: Double-masked, multicenter randomized study with environment and controlled adverse environment (CAE) endpoi

Slide 13: Phase 2b Sign: Statistically Significant Dose Dependent Increase in Tear Production
Phase 2b Sign: AR-15512 demonstrated a statistically significant & dose dependent increase in tear production, a validated endpoint * p < 0.0001 * p < 0.0001 * p < 0.0001 * p < 0.0001 % Responders (>10mm): Unanesthetized Schirmer Score Data on file: Aerie Pharmaceuticals 13 AR-15512 is a development

Slide 14: Phase 2b Sign: Change from Baseline Unanesthetized Schirmer Score
Phase 2b Sign: AR-15512 demonstrated a statistically significant & dose dependent increase in tear production, a validated endpoint * p < 0.0001 * p < 0.0001 Change from Baseline * p < 0.0001 * p < 0.0001 Unanesthetized Schirmer Score Data on file: Aerie Pharmaceuticals 14 AR-15512 is a development

Slide 15: Phase 2b Symptoms: Improvement at Day 14
Phase 2b Symptoms: AR-15512 demonstrated statistically significant improvement at Day 14; continued improvement over time vs. a validated endpoint Symptoms: SANDE score Data on file: Aerie Pharmaceuticals 15 AR-15512 is a development stage product candidate and is not approved by any regulatory agen

Slide 16: Phase 2b: QOL Data Show Improved Functional Vision
Phase 2b: QOL Data Show Improved “Functional Vision” Drive Read Books, etc * p = 0.0138 * p = 0.0202 * p = 0.0135 * p = 0.0243 * p = 0.0117 * p = 0.0053 Data on file Data on file Read Food Labels Watch TV AR-15512 is a development stage product candidate and is not approved by any regulatory agency.

Slide 17: Totality of AR-15512 Phase 2b Data Support Next Steps
Totality of AR-15512 Phase 2b Data Support Next Steps Primary endpoints not achieved. However, statistically significant, dose-dependent improvement observed across multiple time points and validated secondary endpoints Phase 2b Efficacy Data including Schirmer Score, SANDE, ocular discomfort, eye d

Slide 18: DME: ~$2B U.S. Market
1 DME: ~$2B U.S. Market THE PROBLEM • Inflammation and thickening of the macula (macular edema) Macular • Can lead to loss of vision edema CURRENT TREATMENT • Angiogenesis inhibitors & steroids. Patients & providers are dissatisfied with frequent high-cost intravitreal injections required to maintai

Slide 19: Phase 2 Study Objective and Design
Phase 2 Study Objective and Design Objective: Evaluate safety, tolerability, and efficacy of 2 clinical formulations of AR-1105 with same concentration of dexamethasone and different release profiles (CF1, CF2) in subjects with macular edema secondary to retinal vein occlusion (RVO) Design: 6-month,

Slide 20: AR-1105 CF2 Demonstrated Efficacy on Visual Acuity
Phase 2 AR-1105 CF2 demonstrated at least 6 months of efficacy on improving visual acuity 9 Mean Change in Visual 6 1 Acuity (ETDRS Letters) 3 0 Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 CF2 Randomized (n=22) Data on file: Aerie Pharmaceuticals. 1. Error bars are SEM 20 AR-1105 is a d

Slide 21: AR-1105 CF2 Demonstrated Efficacy on Reducing Retinal Edema
Phase 2 AR-1105 CF2 demonstrated at least 6 months of efficacy on reducing retinal edema 0 −100 Mean Change in Central Subfield (Retinal) 1 Thickness −200 Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 CF2 Randomized (n=22) Data on file: Aerie Pharmaceuticals. 1. Error bars are SEM 21 AR-1

Slide 22: AR-1105 Phase 2 Proof-of-Concept Data Support Next Steps
AR-1105 Phase 2 Proof-of-Concept Data Support Next Steps At least 6 months efficacy: improved visual acuity and reducing macular edema Phase 2 Efficacy Data Both formulations well tolerated; no unexpected findings Phase 2 Safety Data Adverse events consistent with other corticosteroids & intravitrea

Slide 23: Wet AMD: ~$4B U.S. Market
1 Wet AMD: ~$4B U.S. Market Blood vessel THE PROBLEM growth, • Abnormal blood vessel growth (angiogenesis) that leaks fluid or leakage blood into the macula, decreasing vision THE OPPORTUNITY 2-4 • 11MM people have some form of AMD (U.S.) • ~1.5MM treated AR-14034/Axitinib implant is a highly select

Slide 24: AR-14034 Preclinical Data Support Up to 12 Months of Efficacy
AR-14034 Preclinical Data Support Up to 12 Months of Clinical Efficacy Drug release data in rabbits predicts up to Proprietary polymer blend maintains high elution rate over time 12-month duration in the clinic Cumulative Release Rate in 1X PBS w/0.5% TWEEN 20 In vitro: In vivo Comparison 100 Percen

Slide 25: Positive AR-14034 Preclinical Data Support Planned IND Filing H2:22
Positive AR-14034 Preclinical Data Support Planned IND Filing H2:22 ® Axitinib is a highly-selective Pan-VEGF blocker (Pfizer’s INLYTA ) Preclinical POC Data Preclinical data supports target 12-month release profile Pre-clinical Safety Data No ocular safety concerns Status IND-enabling studies under

Slide 26: Partnership Opportunities
Partnership Opportunities Santen Glaucoma Agreement ® ® • Rhopressa /Rocklatan • Japan, East Asia, Europe, China, India, CIS* countries, parts of Latin America and Oceania Other Ex-U.S. Out-Licensing Opportunities • AR-15512, AR-1105, AR-14034 Leverage Manufacturing • Improve Athlone, Ireland capaci

Slide 27: Key YE:2021-2022 Milestones
Key YE:2021-2022 Milestones ® ® Rocklatan /Rhopressa Glaucoma AR-15512 Dry Eye AR-14034 Wet AMD Increase adoption & grow sales End of Phase 2 FDA Meeting (Q1:22) File IND (H2:22) H1:2022 H2:2022 YE:2021 Evaluate Phase 3 options for development & commercialization AR-15512, AR-1105 AR-15512, AR-1105

Slide 28: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology ® ® Rhopressa /Rocklatan Growing Glaucoma franchise: Commercial-Stage • U.S.: Net Sales >$115MM+ U.S. run-rate as of Q3:2021 Ophthalmology Company • ROW: Partnership with Santen: EU: Approved, Japan: Phase 3 Two Phase 3-ready programs (in Dry Eye and in DME) Diffe

Slide 29: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology Carolyn McAuliffe Hans Vitzthum ir@aeriepharma.com www.aeriepharma.com For Investor Use Only

Slide 30: Appendix
Appendix For Investor Use Only

Slide 31: AR-15512 Phase 2b Primary Endpoint Signs: Anesthetized Schirmer
AR-15512 Phase 2b Primary Endpoint Signs: Change from Baseline Anesthetized Schirmer (Primary Endpoint) p = 0.494 Data on file: Aerie Pharmaceuticals. LS Mean +/- SE 31 AR-15512 is a development stage product candidate and is not approved by any regulatory agency. For Investor Use Only

Slide 32: AR-15512 Phase 2b Primary Endpoint Symptom: ODS VAS
AR-15512 Phase 2b Primary Endpoint Symptom: Change from Baseline ODS VAS p = 0.23 (Primary Endpoint) * p = 0.028 Data on file: Aerie Pharmaceuticals. LS Mean +/- SE 32 AR-15512 is a development stage product candidate and is not approved by any regulatory agency. For Investor Use Only

Slide 33: An Emerging Leader in Ophthalmology
An Emerging Leader in Ophthalmology Carolyn McAuliffe Hans Vitzthum ir@aeriepharma.com www.aeriepharma.com For Investor Use Only
Source: SEC EDGAR · 8-K filed Jan 5, 2022
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
OIS Glaucoma Innovation Summit 202116 slides · Oct 21, 2021